Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biological and clinical impact of membrane EGFR expression in a subgroup of OC patients from the phase IV ovarian cancer MITO-16A/MANGO-OV2A trial.
Forlani L, De Cecco L, Simeon V, Paolini B, Bagnoli M, Cecere SC, Spina A, Citeroni E, Bignotti E, Lorusso D, Arenare L, Russo D, De Angelis C, Ardighieri L, Scognamiglio G, Del Sesto M, Tognon G, Califano D, Schettino C, Chiodini P, Perrone F, Mezzanzanica D, Pignata S, Tomassetti A. Forlani L, et al. Among authors: bagnoli m. J Exp Clin Cancer Res. 2023 Apr 11;42(1):83. doi: 10.1186/s13046-023-02651-y. J Exp Clin Cancer Res. 2023. PMID: 37041632 Free PMC article.
Simultaneous E-cadherin and PLEKHA7 expression negatively affects E-cadherin/EGFR mediated ovarian cancer cell growth.
Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu ML, Nair-Menon J, Bagnoli M, Bortolomai I, Mezzanzanica D, Canevari S, Kourtidis A, Anastasiadis PZ, Tomassetti A. Rea K, et al. Among authors: bagnoli m. J Exp Clin Cancer Res. 2018 Jul 11;37(1):146. doi: 10.1186/s13046-018-0796-1. J Exp Clin Cancer Res. 2018. PMID: 29996940 Free PMC article.
Choline kinase alpha impairment overcomes TRAIL resistance in ovarian cancer cells.
Rizzo A, Satta A, Garrone G, Cavalleri A, Napoli A, Raspagliesi F, Figini M, De Cecco L, Iorio E, Tomassetti A, Mezzanzanica D, Bagnoli M. Rizzo A, et al. Among authors: bagnoli m. J Exp Clin Cancer Res. 2021 Jan 4;40(1):5. doi: 10.1186/s13046-020-01794-6. J Exp Clin Cancer Res. 2021. PMID: 33390181 Free PMC article.
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M, Canevari S, Califano D, Losito S, Maio MD, Raspagliesi F, Carcangiu ML, Toffoli G, Cecchin E, Sorio R, Canzonieri V, Russo D, Scognamiglio G, Chiappetta G, Baldassarre G, Lorusso D, Scambia G, Zannoni GF, Savarese A, Carosi M, Scollo P, Breda E, Murgia V, Perrone F, Pignata S, De Cecco L, Mezzanzanica D; Multicentre Italian Trials in Ovarian cancer (MITO) translational group. Bagnoli M, et al. Lancet Oncol. 2016 Aug;17(8):1137-1146. doi: 10.1016/S1470-2045(16)30108-5. Epub 2016 Jul 9. Lancet Oncol. 2016. PMID: 27402147 Free article.
A miRNA signature assessing ovarian cancer prognosis.
Bagnoli M, Pignata S, Mezzanzanica D. Bagnoli M, et al. Oncoscience. 2016 Dec 2;3(11-12):308-310. doi: 10.18632/oncoscience.329. eCollection 2016. Oncoscience. 2016. PMID: 28105451 Free PMC article. No abstract available.
Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
Ditto A, De Cecco L, Paolini B, Alberti P, Martinelli F, Leone Roberti Maggiore U, Bogani G, Chiodini P, Pignata S, Tomassetti A, Raspagliesi F, Mezzanzanica D, Bagnoli M. Ditto A, et al. Among authors: bagnoli m. Eur J Cancer. 2022 Jan;161:55-63. doi: 10.1016/j.ejca.2021.11.003. Epub 2021 Dec 15. Eur J Cancer. 2022. PMID: 34922264 Free article.
62 results